Ibandronic acid
- PDF / 169,902 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 96 Downloads / 179 Views
1
S
Osteonecrosis of jaw: case report A 56-year-old woman developed osteonecrosis of jaw during treatment with ibandronic acid for osteoporosis. The woman had a history of osteoporosis and end-stage renal disease secondary to hypertension. She had been receiving treatment with IV ibandronic acid 3 mg/month for 13 months. Her concomitant medications included paricalcitol and calcium acetate. She presented to a dental clinic with a 1-week history of pain in the lower jaw and halitosis. She had poor oropharyngeal/dental health. Oral examination demonstrated posterior alveolar mucosal fistula and inflammation in soft tissue around necrotic bone, limitation in mouth opening (35mm) and a 1.5cm × 0.5cm sized open necrotic bone. A diagnosis of ibandronic acid-associated stage 2 osteonecrosis of jaw was made. On the received panoramic radiogram, size of osteonecrosis was found to be 7cm × 3cm. The woman’s therapy with ibandronic acid was immediately discontinued. She received unspecified antibiotics and oral mouthwash, and underwent oral hygiene training. Additionally, removal of superficial curettage was performed [outcome not stated]. Author comment: "We report a case of [bisphosphonatesrelated osteonecrosis of the jaw] after treatment with intravenous ibandronic acid for osteoporosis." Gunen Yilmaz S, et al. Bisphosphonate-related osteonecrosis of the jaw in a chronic hemodialysis patient. Saudi Journal of Kidney Diseases and Transplantation 29: 223-224, No. 1, 2018. Available from: URL: http:// 803434010 doi.org/10.4103/1319-2442.225187 - Turkey
0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 16 Nov 2019 No. 1779
Data Loading...
